# Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

Study · id `cardio:ct-nct03501680` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03501680](<https://clinicaltrials.gov/study/NCT03501680>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03501680

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03501680. Randomized; no masking; primary purpose treatment. Start 2018-06-06 (anticipated); primary completion 2020-03-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03501680, source copy `cardio:ctgov-nct03501680-2018-06-06`, retrieved 2026-10-31)
- Planned start: 2018-06-06 (anticipated) (ClinicalTrials.gov record NCT03501680, source copy `cardio:ctgov-nct03501680-2018-06-06`, retrieved 2026-10-31)
- Primary completion: 2020-03-08 (anticipated) (ClinicalTrials.gov record NCT03501680, source copy `cardio:ctgov-nct03501680-2018-06-06`, retrieved 2026-10-31)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03501680, source copy `cardio:ctgov-nct03501680-2018-06-06`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03501680-2018-06-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
- Acronym: HAPinsulin
- Condition: Acute Pancreatitis
- Condition: Hypertriglyceridemia
- Intervention (Drug): Insulin
- Intervention (Device): plasmapheresis
- Lead sponsor: First Affiliated Hospital of Wenzhou Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Wenzhou Medical University (`cardio:org-first-affiliated-hospital-of-wenzhou-medical-university`)

## Provenance

Content hash: 7739220fbcdec8fcf813b89d42c5ff4d7c57c861d670007c199f0cf81d87aef8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
